Latest Licensing News

European Lithium Limited reported strong Q2 2025 progress with significant share sales in Critical Metals Corp raising over A$12.8 million, alongside promising exploration and development updates across Greenland, Austria, Ireland, and Australia.

Empire Resources has completed a significant 21-hole reverse circulation drilling campaign at its Yuinmery Project, targeting copper-gold mineralisation across multiple prospects. Assay results are pending, with the company poised to define resource potential amid ongoing exploration.

Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.

Element 25 Limited has locked in AU$50 million in senior debt from the Northern Australia Infrastructure Facility to expand its Butcherbird manganese project, while advancing its US battery-grade manganese refinery with significant government grants and patent protections.

The Star Entertainment Group reported steady Q4 FY25 revenue of $270 million but widened its EBITDA loss to $27 million, reflecting ongoing regulatory pressures and operational challenges. The company secured $233 million from strategic investors Bally’s Corporation and Investment Holdings, while negotiations continue over its Brisbane joint venture exit.

Nickel Industries reported record ore sales and EBITDA at its Hengjaya Mine for the June 2025 quarter, alongside significant progress on key projects and sustainability initiatives.

Netlinkz Limited reported $979,000 in quarterly receipts and a landmark $1 million VSN license sale in the Philippines, while advancing significant cost reductions and debt restructuring efforts.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Emerald Resources NL reported steady gold output at its Okvau Mine while unveiling significant resource expansions at its Dingo Range and Memot projects, alongside clearing its debt.